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Abstract: Antigen-presenting cells (APCs) play an important role in the development of autoimmune diseases. These 
cells recognize pathogen associated molecular patterns but also endogenously produced ligands through toll-like receptors 
(TLRs). Aberrant activation of these receptors and the following intracellular signaling pathways can induce the deleteri-
ous production of pro-inflammatory cytokines. In genetically predisposed individuals this might lead to a breach in toler-
ance and eventually autoimmunity. IgG and IgG immune complexes (ICs), which are abundantly present in autoimmune 
diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc) are recognized 
by APCs via Fc gamma receptors (FcRs) and can also modulate their activation state. Upon their uptake specific antigens 
present in ICs are capable of stimulating APCs via their intracellular TLRs, increasing their capability to induce (autoreac-
tive) T and B cell responses. This underscores their likely role in the generation and maintenance of autoimmunity. By fo-
cusing on three autoimmune diseases, SLE, RA and SSc, we will illustrate the importance of TLRs and FcRs in the 
pathogenesis of autoimmune diseases.  
Keywords: Toll Like Receptors, Fc gamma receptors, Antigen-presenting cells, Systemic lupus erythematosus, Rheumatoid 
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INTRODUCTION 
 Most systemic autoimmune disorders, such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) and 
systemic sclerosis (SSc) are diagnosed by the use of a set of 
defined classification criteria mirroring their phenotypic het-
erogeneity [1-3]. Variation in the underlying etiologic fac-
tors, such as environmental factors and the genetic back-
ground, seems to underlie this clinical complexity and phe-
notypic variability. A crucial etiologic factor seems to be the 
presence of specific antibodies aimed at endogenous ligands. 
Antibodies of the IgG type and IgG containing immune 
complexes (IC) are recognized by Fc gamma receptors 
(FcRs). These receptors are expressed by many kinds of 
immune cells including antigen-presenting cells (APCs) such 
as myeloid and plasmacytoid dendritic cells (DC), mono-
cytes and macrophages. The family of FcRs consists of the 
high affinity FcRI and the low affinity FcRIIa, IIb, IIc, IIIa 
and IIIb. FcRIIb is the only FcR with an immunoreceptor 
tyrosine-based inhibition motif (ITIM) instead of an activa-
tion motif (ITAM). IC binding to activating FcRs can in-
duce phagocytosis, antigen presentation, pro-inflammatory 
cytokine production and antibody-dependent cellular cyto-
toxicity. The simultaneous activation of the inhibitory 
FcRIIb inhibits these processes and can prevent the pro-
inflammatory actions caused by the activating receptors [4]. 
The resulting immune response upon the binding of IC thus 
depends on the balance between the activating and inhibitory 
FcRs. Activation of FcRIIa on monocyte-derived DCs re-
sults in DC maturation, increased stimulation of allogeneic T  
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cells, and enhanced secretion of inflammatory cytokines, 
while preferential activation of FcRIIb keeps DCs more 
immature, decreases the stimulation of allogeneic T cells and 
favors the development of Th2 responses even in the pres-
ence of a strong stimulus like lipopolysaccharide [4, 5].  
 It is widely recognized that a loss of immune tolerance to 
self components due to aberrant B and T cell reactivity is the 
shared basis of complex immune diseases such as SLE, RA 
and SSc. Type I interferons (IFNs) appear to play a crucial 
role in the breakdown of self tolerance. The finding that ap-
proximately 20% of patients treated with IFNs for various 
disorders develop an autoimmune disease underpins this 
notion [6]. IFNs are prototypically released by APCs, espe-
cially plasmacytoid DC (pDC), upon the activation of nu-
cleic acid sensing TLRs. TLRs are pattern recognition recep-
tors capable of recognizing both endogenous molecules re-
leased upon cell stress and a wide range of conserved con-
stituents from pathogens [7-9]. Four intracellular TLRs ca-
pable of sensing nucleic acids are found in APCs. TLR3 is 
activated by double stranded RNA (dsRNA), TLR7 and 
TLR8 by single stranded RNA (ssRNA) and TLR9 by un-
methylated CpG DNA. Another TLR known for its capabil-
ity to induce the release of IFNs is TLR4. TLR4 is expressed 
extracellular and recognizes lipopolysaccharides (LPS) from 
bacteria and a wide range of endogenous ligands [10]. An 
important part of its intracellular signaling cascade is shared 
with TLR3 explaining its capability of triggering IFN pro-
duction. TLRs are highly suspected as conductors of auto-
immunity [11]. The activation of multiple TLRs leads to the 
release of copious amounts of pro-inflammatory cytokines 
creating a volatile situation. In genetically predisposed indi-
viduals this might eventually lead to a breach in tolerance 
culminating in autoimmune disease [12]. The intracellular 
localization of the nucleic acid sensing TLRs prevents aber-
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rant activation of APCs by endogenous nucleic acids. In 
many autoimmune diseases however antibodies have been 
found aimed at nucleic acids or proteins bound to these, ena-
bling endocytosis of these ICs resulting in TLR activation by 
normally harmless components of self [13, 14]. This review 
focuses on FcR and TLR and their interplay in three proto-
typical autoimmune diseases, SLE, RA and SSc character-
ized by autoantibody production and likely mediated by an 
aberrant activation of TLR expressing APC.  
SYSTEMIC LUPUS ERYTHEMATOSUS 
 As a hallmark autoimmune disease SLE is a very hetero-
geneous disease. Individual patients vary in terms of the 
presence of specific auto-antibodies and the involvement of 
skin, kidneys, joints, the nervous system and other organs. 
The disease primarily affects women with a ratio of 9:1 
compared to males [15]. Excess formation of ICs due to the 
production of auto-antibodies causing inflammation and sub-
sequent tissue damage seems to be the main immunological 
event in SLE. Highly specific antibodies for SLE are those 
aimed at dsDNA and the Sm proteins (a protein complex that 
binds small nuclear RNAs). Anti-dsDNA antibodies reflect 
disease activity in SLE, especially the activity of lupus ne-
phritis [16]. Deposited ICs will induce inflammation by acti-
vating FcR-bearing immune cells such as monocytes, 
macrophages and plasmacytoid and myeloid DCs.  
 Since the genetic contribution to SLE is thought to be 
relatively large [17], it seemed likely that a genetic signature 
would be identified in SLE patients increasing their risk for 
the development of auto-antibodies and/or an increased reac-
tion toward these. A fitting association has been found be-
tween genes within the human leukocyte antigen (HLA) re-
gion on the short arm of chromosome 6 (6q21.3), especially 
in the major histocompatibility complex HLA-DRB1 and –
DQB1 loci. Polymorphisms of these determine the fitting of 
certain epitopes and thus their presentation by APCs to T 
cells. Therefore these polymorphisms determine the produc-
tion of specific auto-antibodies against nuclear antigens and 
the risk of developing SLE [18, 19]. Linked to the aberrant 
tissue deposition of ICs in SLE, preliminary evidence asso-
ciates variants of FcRIIa and IIIa with the development of 
SLE [20, 21]. These variants have been found to be less ef-
fective than their more frequent counterparts in binding ICs, 
implicating accumulation of ICs in specific tissues as an 
etiologic event in SLE. Another well-documented risk factor 
for SLE lies in the interferon regulatory factor 5 (IRF5) 
gene. The variants associated with an increased risk to SLE 
confer an augmented function of IRF5 by increasing its ex-
pression [22-24]. IRF5 is tightly involved in the signaling 
pathway utilized by TLRs activating the transcription of type 
I IFN and related proteins in APCs [25]. Since TLR7 and 
TLR8 recognize ssRNA and TLR9 recognizes unmethylated 
CpG dinucleotide containing single stranded as well as dou-
ble stranded DNA, these receptors are thought to be heavily 
involved in the pathogenesis of SLE [26]. Single nucleotide 
polymorphisms (SNPs) in STAT4, increasing its expression, 
were recently found by Sigurdsson et al. [27] to be associ-
ated with SLE. The presence of these SNPs correlated with 
the production of antibodies against dsDNA. STAT4 is acti-
vated by the ligation of the IFN receptor and is subse-
quently translocated to the nucleus, in mature DCs this in-
duces the transcription of various factors resulting in en-
hanced T cell activation [28]. In addition STAT4 transmits 
signals from the receptors of IL-12p70 and IL-23 and is cru-
cial for the development of the Th1 lineage in humans [29]. 
Interestingly, IRF5 and STAT4 are, in addition to SLE, se-
lectively associated with an increased risk for other autoim-
mune diseases with an interferon signature such as RA and 
SSc, implicating common etiologic pathways for the breach-
ing of tolerance. 
 Keeping these genetic predispositions in mind it is in-
triguing to see that the involvement of APCs and their anti-
gen uptake receptors in the pathogenesis of SLE is strongly 
supported by in vivo and in vitro human data. Raised serum 
levels of IFN have been observed in SLE patients and cor-
related with disease severity [30]. In addition peripheral 
blood cells of SLE patients demonstrated an increased tran-
scription level of type I IFN regulated genes, probably be-
cause of a continuous production of IFN [31]. A crucial 
causative role in the induction of this IFN profile might be 
the presence of RNA or DNA containing ICs. The common 
auto-antibodies in SLE like anti-dsDNA, anti-Sm proteins, 
anti-Ro proteins and anti-histone antibodies bind to either 
dsDNA or proteins complexed with RNA or DNA. These 
ICs are taken up via FcRs by APCs and by B cells via the B 
cell antigen receptor [12]. When these ICs reach the en-
dosome they subsequently trigger the intracellular TLR7, 
TLR8 or TLR9. This leads to the production of pro-
inflammatory cytokines, such as type I IFNs, the up regula-
tion of IFN regulated genes, the maturation of APCs and the 
presentation of self peptides to autoreactive T cells [32-34]. 
These autoreactive T cells in turn can help B cells in the pro-
duction of auto-antibodies. In itself, the direct activation by 
nucleic acid-containing IC of B cells additionally promotes 
auto-antibody production [35]. APCs of special interest in 
SLE are the plasmacytoid DCs. They were demonstrated to 
be the main producers of type I IFN upon stimulation with 
dsDNA or Sm containing ICs. These interferogenic ICs are 
taken up by plasmacytoid DC via FcRIIa, are translocated 
to the endosome and then stimulate the relevant TLR result-
ing in a massive release of IFN [36, 37]. However, since 
monocytes, macrophages and myeloid DCs express high 
levels of FcRs and respond vigorously to stimulation with 
TLR7/8 ligands, nucleic acid containing ICs might also acti-
vate these cells to produce pro-inflammatory cytokines. This 
was previously demonstrated by Boulé et al. using murine 
bone-marrow DCs which produced TNF and BAFF upon 
the stimulation with chromatin IC [32]. Myeloid DCs, upon 
the activation with TLR7/8 ligands are able to secrete high 
levels of IL-12p70 and induce the proliferation of Th1 cells, 
especially in combination with IFN, IFN or TLR4 ligands 
[10, 38, 39]. IL-12p70 is the major cytokine in inducing Th1 
responses and thus the production of IFN. Blood IL-12p70 
and IFN are elevated in SLE patients and IL-12p70 levels 
correlate with the SLE disease activity index (SLEDAI) in 
SLE patients with renal involvement [40, 41]. Correspond-
ingly, the ratio of IFN/IL-4-producing CD4+ T cells corre-
lates with the SLEDAI and was significantly higher among 
patients with lupus nephritis [42]. In addition, IFN was 
demonstrated to contribute heavily to nephritis in murine 
lupus [43]. Nucleic acid-containing ICs may thus start a vi-
cious circle by inducing IFN from plasmacytoid DCs. In 
this conceptual framework the released IFN then primes 
monocytes and myeloid DCs for TLR7/8 activation by nu-
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cleic acid containing ICs resulting in a synergistic release of 
IL-12p70. The high levels of IL-12p70 favor the presence of 
Th1 cells and thus the release of IFN. IFN in itself primes 
myeloid lineage cells for the internalization of ICs, the re-
lease of IL-12p70 and the presentation of self peptides to 
autoreactive T cells enabling them to help B cells produce 
antibodies against nucleic acids or proteins bound to these. 
An observation supportive of this hypothesis was that in 
SLE, monocyte-derived and myeloid DCs are in a pre-
activated state promoting DC maturation, pro-inflammatory 
cytokine release and T cell proliferation [44]. Interestingly, 
as described above, genes involved in the production of type 
I IFN and IL-12p70 (IRF5) and its signal transduction in 
APCs and T cells (STAT4) are heavily implicated in the sus-
ceptibility for SLE and might thus contribute to this self-
sustaining menacing loop [22-24, 27]. An additional mecha-
nism which might support this vicious circle is the myeloid 
DC-inducing capacity of SLE serum, mediated through the 
effect of IFN on monocytes [45]. The promotion of the 
differentiation of B cells into plasmablasts and antibody-
secreting plasma cells by pDCs activated with SLE ICs 
seems to be another contributing factor [46]. Of interest, 
crossing of mice lacking the inhibitory FcRIIb to the Y-
linked autoimmune accelerator (Yaa) locus, which harbors a 
duplication in the TLR7 gene, markedly enhanced autoim-
munity [47], stressing the importance of FcR and TLR co-
operation in the maintenance of tolerance and the induction 
of autoimmunity.  
 The involvement in the pathogenesis of SLE of the type I 
IFN system consisting of nucleic acid containing ICs and 
TLRs has been subject of intense investigation during the 
past years in animal models of SLE. A large body of suppor-
tive data has emerged from these studies. The importance of 
signaling through the IFN receptor was apparent from ex-
perimental murine lupus models in which IFN receptor 
knock-out mice had a markedly reduced SLE disease [48]. 
The essential role played by TLR7 in the pathogenesis of 
SLE was emphasized by studies demonstrating that mice 
lacking this receptor do not produce anti-Sm antibodies and 
have an ameliorated clinical disease [49]. The blockade of 
TLR7 with synthetic oligodeoxynucleotides in MRL(lpr/lpr) 
mice also reduced the levels of anti-Sm and anti-dsDNA 
antibodies and ameliorated lupus nephritis [50, 51]. In addi-
tion, over expression of TLR7 accelerated systemic autoim-
munity in murine lupus [52]. The role for TLR9 was less 
clear, whereas triggering of TLR9 with CpG oligonucleo-
tides in MRL(lpr/lpr) mice induced nephritis [53]. Absence 
of this receptor accelerated clinical disease in MRL(lpr/lpr) 
mice although it did prevent the occurrence of anti-dsDNA 
antibodies [54].  
 These emerging data suggestive of a causal relationship 
between auto-antibodies, an over-activated type I IFN sys-
tem and SLE indicate that these could be therapeutic targets. 
Supportive are data from two effective therapeutic agents in 
SLE, hydroxychloroquine and glucocorticoids. These drugs 
prevent activation of the intracellular TLRs, inhibit IFN 
production by pDCs and suppress the IFN signature [55, 56]. 
Interestingly, preliminary results from a phase I clinical trial 
with a neutralizing antibody against IFN were very encour-
aging with a dose-dependent inhibition of type I IFN-
inducible genes as well as a prominent reduction in clinical 
disease activity [57]. In another clinical trial (phase III) an 
agent (Abetimus sodium) selectively aimed at removing anti-
dsDNA antibodies from the blood was used. Although not all 
clinical parameters improved notably a significant reduction 
in SLEDAI and proteinuria was observed corresponding to 
the reduction of circulating anti-dsDNA antibodies, under-
scoring the pathological role of these antibodies. A possible 
explanation for the limited clinical effect of this agent might 
be that the remaining RNA-containing IC induced sufficient 
amounts of IFN to maintain the chronic inflammatory 
process [58].  
RHEUMATOID ARTHRITIS 
 RA is a systemic autoimmune disease characterized by 
chronic synovial inflammation and subsequent damage to 
cartilage and bone, leading to severe disabilities. Most RA 
patients have auto-antibodies against the Fc portion of IgG 
molecules (Rheumatoid Factor) and citrullinated proteins. 
The most frequent proteins against which anti-citrullinated 
protein/peptide antibodies (ACPAs) are produced are fi-
brinogen and -enolase, which are abundantly present in the 
RA synovium [59, 60]. The presence of these auto-
antibodies is associated with a more aggressive disease 
course suggesting a pathogenic role in RA [61]. There is a 
large disease heterogeneity highlighted by different re-
sponses to medication such as the anti-TNF antibodies.  
 During RA there is a massive influx of immune cells into 
the synovial cavity, including monocytes, macrophages, 
dendritic cells (DCs), T cells and B cells. Genetic evidence 
points towards an important role for APCs and their antigen-
uptake receptors in the pathogenesis of RA. The strongest 
association with RA susceptibility and disease severity has 
been found in the HLA-DRB1 gene [62-64]. Multiple RA 
risk alleles within the HLA-DRB1 gene share a conserved 
amino acid sequence and are therefore known as ‘shared 
epitope’ alleles [65]. These polymorphisms are present in the 
epitope binding region of the major histocompatibility com-
plex II (MHC) and thereby probably influence antigen pres-
entation by APCs and autoantibody production [66]. Recent 
data shows that shared epitope alleles of the MHC-II are 
specifically associated with anti-CCP positive RA [67, 68]. 
More recently also non-HLA genes have been linked to RA 
susceptibility and disease severity. Variants of the activating 
Fc gamma receptors FcRIIIa and FcRIIIb have been asso-
ciated with RA susceptibility in Europeans, but not in Asians 
[69, 70]. The FcRIIIa variant is less effective in IC binding, 
implicating impaired clearance of ICs might play a role in 
the pathogenesis of RA, similar to SLE[71]. A functional 
variant of the inhibitory FcRIIb is associated with disease 
severity rather than susceptibility [72]. APCs from patients 
with this variant fail to develop an inhibitory phenotype 
upon IC binding, thereby stimulating pro-inflammatory im-
mune responses and subsequent joint damage. Similar to 
SLE, the IRF5 and STAT4 genes are also important risk fac-
tors for RA [73, 74]. These genes are involved in the type I 
IFN system in APC, activated as a part of the TLR signaling 
pathway. These common denominators suggest that, like in 
SLE, the type I IFN system might play a role in the breach-
ing of tolerance in RA. TLR involvement is further sug-
gested by a functional variant of the TLR4 gene that reduces 
the response to LPS and thereby decreases the susceptibility 
to RA [75], although not significant in another study [76].  
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 The involvement of APCs and their antigen uptake recep-
tors in the pathogenesis of RA is not restricted to genetic 
predisposition, but is further supported by in vitro and in 
vivo data. In RA synovial tissue, the expression of TLR2, 3, 
4 and 7 is increased compared to healthy controls or os-
teoarthritis patients [39, 77-79]. RA synovial fibroblasts pro-
duce increased amounts of chemokines upon stimulation 
with TLR2 ligands [80]. Similarly, monocyte-derived DCs 
from RA patients also show an increased responsiveness to 
TLR2 and TLR4 ligands, resulting in increased production 
of pro-inflammatory cytokines [39]. Tissue damage and cell 
stress during synovial inflammation can lead to the produc-
tion of heat shock proteins (HSPs), altered fibronectin or low 
molecular weight hyaluronan fragments and RNA release 
from necrotic cells. These are endogenous TLR ligands that 
in turn can activate synovial fibroblasts and APCs via TLR2, 
TLR4 and TLR3, stimulating chronic inflammation [9, 78, 
81-83]. Necrotic cells in the RA synovium may also release 
citrullinated proteins and activated citrullinating peptidy-
larginine deaminases (PADs). These enzymes can citrullinate 
for example fibrin(ogen) present in large amounts in the RA 
synovium. When these proteins are not degraded properly, 
they can be taken up by APCs and presented to T cells which 
in turn can trigger autoreactive B cells to produce ACPAs. 
Locally produced ICs can induce TNF production by 
monocytes and macrophages via FcRIIa and thereby aggra-
vate local inflammation and promote chronicity [84-86]. 
Recently, TLR8 has also been shown to be important for 
TNF production in RA synovial tissue. Inhibition of TLR8 
was able to inhibit spontaneous TNF production by RA 
synovial membrane cultures [87]. Stimulation of TLR8 by an 
unknown ssRNA containing component present in the RA 
synovium appears to lead to pro-inflammatory cytokine pro-
duction, including type I IFNs, and might support APC 
maturation and subsequent presentation of (self) peptides to 
(autoreactive) T cells. These findings, together with genetic 
data concerning IRF5 and STAT4, are indicative of a role for 
type I IFNs in RA. Supportive of this are the high levels of 
IFN found in RA synovial tissue and the selective up regu-
lation of type I IFN-response genes in peripheral blood cells 
from a subgroup of RA patients [10, 88]. In addition, it was 
recently reported that SLE features are common in RA pa-
tients given sufficient observation time and that these were 
associated with increased mortality [89]. Refuting a role for 
type I IFN in the pathogenesis of RA are the clinical advan-
tages that have been made in RA using anti-TNF antibod-
ies. The production of type I IFN by plasmacytoid DCs is 
enhanced by blocking TNF [90]. A known side effect of 
anti-TNF therapy is the occurrence of antinuclear antibod-
ies and anti-dsDNA antibodies which might even culminate 
in full-blown glomerulonephritis [91]. However, even anti-
TNF therapy is successful in only a subpopulation of RA 
patients underscoring the existence of diverse pathways lead-
ing to autoimmunity. As in SLE, it might be possible that the 
endocytosis pathway by which the ssRNA is delivered to the 
intracellular TLR8 is mediated via antibodies and FcRs. 
Immune complexes in joints might thus provide a direct link 
to cytokine dependent inflammation in RA, via APCs. Co-
herently, APCs from RA patients have been shown to pro-
duce more TNF upon IC triggering than healthy control 
APCs, which can be explained by increased expression of 
FcRII and FcRIII on these cells [92, 93]. High expression 
of the inhibitory FcRIIb could play an important role in 
controlling inflammation by inhibition of activating FcRs 
and TLR4 induced cytokine production in macrophages and 
DCs [5, 94]. Highly increased FcRIIb expression on mono-
cyte-derived DCs from RA patients that have sustained low 
disease activity without the need of medication underscores 
the importance of this feedback mechanism in RA [5].  
 FcR knockout studies confirm the important role of 
FcRs in arthritis. Several studies have shown that the pres-
ence of activating FcRs was associated with increased 
chondrocyte death and cartilage erosion and that FcRIII 
knockout mice are protected from IC-induced arthritis[95-
99]. Inhibition of spleen tyrosine kinase (Syk), a key media-
tor of activating FcRs and B cell receptor signaling, also 
shows suppression of inflammation and bone erosion, high-
lighting a possible role of activating FcRs in arthritis mod-
els [100]. On the other hand, deletion of the inhibitory 
FcRII (mice lack FcRIIa) induced arthritis even in non-
susceptible mice [101]. FcRIIb not only inhibits activating 
FcRs, but is also important for effective clearance of ICs 
[102]. Furthermore, FcRIIa transgenic mice are hyper-
responsive to pathogenic antibodies and blocking of this re-
ceptor in these mice inhibited development and stopped pro-
gression of collagen-induced arthritis [103]. These data 
clearly show the importance of activating FcRs on APCs in 
the initiation and progression of arthritis, which is in line 
with the in vitro data showing involvement of activating 
FcRs in pro-inflammatory cytokine production and inhibi-
tion of this by FcRIIb. Experimental arthritis models have 
also contributed to our understanding of the role of TLRs in 
RA. Classical animal models such as streptococcal cell wall 
(SCW) arthritis and autoimmune arthritis in IL-1 receptor 
antagonist-knockout (IL-1ra-/-) mice are dependent on acti-
vation of the innate immune system via TLRs. The acute 
phase of SCW induced arthritis is dependent of TLR2, while 
the TLR dependency shifts towards TLR4 in the chronic 
phase. This occurs simultaneously with the transition from a 
macrophage driven arthritis to a T cell dependent process 
[102]. Arthritis development in IL-1ra -/- mice can also be 
regulated by TLRs, since TLR2 knockout mice develop a 
more severe arthritis while TLR4 knockouts were protected 
against severe arthritis. Selective blocking of TLR4 was also 
able to diminish severity of experimental arthritis [104]. A 
role for TLRs is further supported by studies that show a 
self-limited form of arthritis in mice after synovial injection 
of TLR ligands, such as CpG DNA, dsRNA or staphylococ-
cal peptidoglycans [105-107].  
 APCs and their cytokines have been proven to be an ef-
fective therapeutic target in the treatment of RA. Therapies 
often used now are biologicals directed against effector 
molecules like TNF (adalimumab, etanercept, and inflixi-
mab), IL-6 (tocilizumab) or IL-1 (anakinra), molecules pro-
duced by APCs as a response to TLR stimulation or antigen 
uptake via FcRs. The development of TNF antagonists had 
a great impact on treatment of RA patients, although still 
about 30% of the patients fails to respond to TNF antagonists 
or has to discontinue treatment due to adverse effects [108, 
109]. Another effective therapy directed against APCs is 
abatacept, which binds to CD80/CD86 on the APC and pre-
vents T cell activation [110-112]. Medication more specifi-
cally directed against antigen-uptake receptors or TLRs are 
already used for several years and more are under investiga-
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tion. The combination of methotrexate and hydroxychloro-
quine, which prevents intracellular TLR activation, shows 
increased effectiveness compared to methotrexate alone 
[113-116], although this might partially be due to an in-
creased bioavailability of methotrexate [117]. The effective-
ness of direct targeting of TLRs in RA is also supported by a 
phase II clinical trial with chaperonin 10, that inhibits TLR2 
and TLR4 signaling [118]. No placebo was used in this trial, 
so confirmation of its potential is necessary, but it suggests 
quick and sustained improvement of symptoms during the 12 
weeks follow up. However, there are some considerations 
concerning possible adverse effects during long-term use, 
since chaperonin 10 has also been described in carcinogene-
sis [119, 120]. Long term studies have to show if chaperonin 
10 could be used in the treatment of RA or not. Since Syk is 
involved in FcR and B cell receptor signaling inhibition of 
this tyrosine kinase could reduce IC mediated inflammation 
and B cell responses, suggesting great potential in RA treat-
ment. A 12 week, randomized clinical trial has already dem-
onstrated superior clinical efficacy of an oral Syk kinase 
inhibitor, R788 compared to placebo [121].  
SYSTEMIC SCLEROSIS 
 Systemic sclerosis (SSc) is a heterogenous autoimmune 
disease characterized by fibrosis of the skin and the internal 
organs, leading to sever debilitation and eventually death. 
The prevalence and incidence of SSc varies greatly depend-
ing on geographical location and ethnicity but it is clear that 
women are affected more often than men with a ratio ranging 
from 4:1 to 14:1 [122]. Over the past year clinical outcomes 
have improved, presumable due to better management of 
complications, but still SSc is considered incurable. As most 
autoimmune diseases SSc is a heterogeneous disease. Clini-
cally it can be subdivided in two entities on the extent of skin 
involvement; limited SSc (limSSc) defined as fibrosis distal 
to the elbow and knee joint and the face, and the diffuse 
form with more proximal fibrosis [2]. The diffuse cutaneous 
form (dSSc) is the most fatal connective tissue disease 
known with 55% survival at 10 years [123]. The etiology is 
still unknown but prominent features are vascular injury and 
chronic inflammation resulting in fibrosis. Evidence for an 
autoimmune process causing this inflammation is growing, 
for example exposed by the presence of auto-antibodies in 
90% of SSc patients.  
 As for the autoimmune diseases described above, the 
genetic make-up seems to determine the chance of develop-
ing SSc in response to an external trigger. This is demon-
strated by the fact that a positive family history is the strong-
est risk factor thus far identified in SSc [124] although con-
cordance is still weak [125]. Furthermore SSc is now associ-
ated with a sizable number of SNPs in an increasing number 
of genes [126]. Like in other autoimmune diseases the HLA 
region is a region of interest in SSc. However there is a lack 
of consensus concerning the contribution of these alleles in 
SSc. A consistent finding in this discussion seems to be the 
association between anti-topoisomerase I (anti-topo I) and 
the HLA-DR region [127-129] suggesting a contribution of 
auto-antibodies in the pathogenesis. As reported in SLE and 
RA there is an association between the possession of the 
SNP rs2004640 in IRF5 and susceptibility to SSc [130] (and 
unpublished observations). This SNP results in the produc-
tion of a different isotype from IRF5 leading to a different 
transcription of target pro-inflammatory cytokines which are 
known to increase the risk for developing SLE [131]. Next to 
that, recent data show an association between STAT-4 SNPs 
and disease phenotype favoring limited SSc [132]. Both as-
sociations suggest a role for TLR signaling and the IFN 
pathway in SSc as shown for SLE and RA but further re-
search to unravel consequences of these SNPs is needed. 
 Anti-topo I and anti-centromere antibodies (ACA) are 
generally known to characterize specific clinical subsets with 
Anti-topo I being more prevalent in dSSc and ACA in 
limSSc [133]. In line with findings in SLE, data on an IFN 
type I signature are growing [134-136] and a recent report 
from Kim et al. [137] showed interferogenic activity by anti-
topo I ICs. Although a role for type I IFNs in SSc is counter-
intuitive knowing that these IFN are potent inhibitors of col-
lagen production in fibroblasts [138], a report describing the 
rapid onset of SSc symptoms in patients treated with intense 
IFN therapy suggests a clear pathologic contribution of 
IFNs to the development of SSc [139]. In view of this, plas-
macytoid DC (pDCs) are interesting due to their potential of 
producing high levels of type I IFNs. Kim et al. showed that 
interfering with FcRIIa or RNAse treatment suppresses the 
IFN production upon stimulation with anti-topo I antibodies 
[137]. This implicates that like anti-Sm antibodies in SLE, 
anti-topo I antibodies are taken up by pDCs via FcRIIa and 
subsequently activate TLR7 inducing the production of 
IFN. In contrast, ACA did not induce the production of 
IFN. Since anti-topo I and ACA are predominantly found 
in patients with dSSc and limSSc, respectively, a role for 
IFN in disease severity seems likely. Type I IFNs have a 
known anti-angiogenic and pro-apoptotic effect on endothe-
lial cells implicating a role in SSc vascular distress. High-
lighting this, endothelial cells in SSc express a type I inter-
feron signature [134, 140]. In the last years more auto-
antibodies were identified and their contribution to the dis-
ease was investigated. For example, antibodies directed 
against FcR and especially FcRIII were described. This 
was suggested to reduce the ability of FcR to phagocytose 
immune complexes [141, 142]. Other antibodies target fi-
broblasts (anti-fibroblast antibodies (AFA) and anti-platelet-
derived growth factor (PDGF) receptor) [143]. Stimulation 
of fibroblasts through TLR4, possibly by these auto-
antibodies, up regulates a chemokine transcription program, 
skewed towards pro-fibrotic activities, for example increased 
CCL2 production. The importance of this is illustrated by the 
fact that CCL2 is abundantly present in SSc [144-147] and 
most interestingly CCR2-/- mice are resistant to the devel-
opment of lung fibrosis induced by bleomycin [148]. More 
intriguing recent literature suggests that signaling through 
TLRs plays a role in maintaining the heightened state of ac-
tivation of the myofibroblast as seen during fibrosis [149]. 
These findings together with the presence of endogenous 
TLR4 ligands in the circulation of SSc patients [39] suggests 
that signaling through these receptors could induce chronic 
systemic fibrosis in the susceptible host.  
 An initial pathological finding in SSc dermal tissue is 
rarefaction of capillaries and the infiltration of mononuclear 
cells [150, 151]. These cellular infiltrates consist mainly of 
myeloid APCs and CD4
+
 T-cells. The role of the immune 
system in the development of SSc has been investigated in 
several animal models. In UCD 200 chicken, for example, 
dermal and visceral fibrosis is also preceded by mononuclear 
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infiltration demonstrating the role of inflammatory cells in 
initiating fibrosis [152, 153]. Thight Skin-2 mice (Tsk-2), 
another SSc animal model, also show this early mononuclear 
cell infiltration together with autoantibody production re-
sembling human SSc [154, 155]. Bleomycin is a glycopep-
tide antibiotic used as a chemotherapeutic agent, well-known 
side effects are lung fibrosis and Raynaud’s phenomenon. 
Repeated subcutaneous injections of bleomycin in shaved 
back skin induced dermal fibrosis closely resembling SSc 
[156]. In the murine bleomycin model immune cells are acti-
vated by hyaluronan via TLR4 (and directly by bleomycin 
via TLR2 [157]) and auto-antibody production is induced 
resulting in a scleroderma like phenotype [158].  
 The increasing amount of evidence illustrating the role of 
APCs in the pathogenesis of SSc can offer new insights in 
the pathogenesis of this disease and thus offer new therapeu-
tic targets. As an example, the data above suggest that in SSc 
APCs infiltrate the diseased tissue, are activated through 
their TLRs and activate a cascade resulting in fibrosis. Inter-
fering in this cascade is just one interesting example. A 
therapeutic target might be BDCA-2, a C-type lectin receptor 
exclusively present on pDCs. Ligation of BDCA-2 inhibits 
the production of type I IFN of pDCs upon anti-topo I stimu-
lation by interfering with the uptake via FcRIIa and signal-
ing through TLRs [137]. Activation of pDC via BDCA-2 
might thus reduce the pro-inflammatory and anti-angiogenic 
effect of these ICs. Current therapeutic options in SSc are 
very limited. Administrations of cyclophosphamide or 
autologous stem cell transplantation currently are the only 
therapies with some effect [159], although the results of the 
bigger trials are still to be expected [160]. As these therapies 
attack the whole cellular balance it is impossible to speculate 
on a specific contribution.  
CONCLUSION  
 A large body of evidence points towards a seminal role 
for APCs and their uptake receptors in the development of 
autoimmune diseases. Striking similarities in many genetic 
and pathophysiological features in autoimmune diseases like 
SLE, RA and SSc were described despite their apparent dis-
similar characteristics (Table 1). A fitting explanation for 
this issue appears to be the HLA-DRB1 gene which is asso-
ciated with all these diseases. Since there is almost no over-
Table 1. Highlighting Some Current Data Available on the Role Played by APCs, their FcRs and TLRs and their Products 
 SLE RA SSc 
Genetics 
(associated 
genes impor-
tant in the 
function of 
APCs) 
HLA-DRB1/DQB1 [18,19] 
FcRIIa and FcRIIIa [20,21] 
IRF5 [22-24] 
STAT4 [27] 
HLA-DRB1 [62-64] 
FcRIIIa/b and FcRIIb [69-72] 
IRF5 [73] 
STAT4 [74] 
HLA-DR [127-129] 
IRF5 [130] 
STAT4 [132] 
In vivo  Increased transcription of type I IFN 
regulated genes in peripheral blood cells. 
[31] 
Increased levels of IFN correlated with 
disease severity. [30] 
Increased IL-12p70 levels correlating 
with SLEDAI. [40,41] 
Increased TLR2, 3, 4, 7 expression and pres-
ence of endogenous TLR4 ligands in RA 
synovial tissue. [39, 77-79] 
Increased transcription of type I IFN regu-
lated genes in blood. [88] 
IFN expression in RA synovial tissue. [10] 
Increased transcription of 
certain type I IFN regulated 
genes in peripheral blood 
cells. [135] 
Endogenous TLR4ligands in 
serum. [39] 
Myeloid APCs in diseased 
skin. [150-151] 
In vitro ICs from SLE patients induce the release 
of IFN by plasmacytoid DCs via TLR7 
and TLR9. [36,37] 
Monocyte-derived and myeloid DCs 
from SLE patients demonstrate increased 
maturation and cytokine release. [44] 
RA synovial tissue fibroblasts and mono-
cyte-derived DCs display an increased re-
sponse to TLR stimulation. [39,80] 
ICs in synovial fluid induce TNF release 
from monocytes. [92,93] 
TLR8 inhibition prevents “spontaneous” 
cytokine release by synovial tissue. [87] 
Interferogenic activity of anti-
topoisomerase ICs on plas-
macytoid DCs. [137] 
 
Animal 
models 
TLR7-/- mice do not develop anti-Sm 
antibodies and have a less severe disease. 
[49] 
TLR7 over expression results in in-
creased autoimmunity. [52] 
IFNR-/- mice develop less severe lu-
pus-like disease. [48] 
FcRIII-/- mice are protected from IC-
induced arthritis. [97, 99] 
FcRII-/- mice are more susceptible and have 
a worse arthritis. [101] 
Knocking out of TLR4 or the blockade of 
TLR4 reduces arthritis in multiple models. 
[102, 104] 
Syk inhibitors suppress inflammation and 
bone erosion. [100] 
UCD 200 chicken, Tsk2 mice 
and bleomycin induced SSc 
show mononuclear cell infil-
trates and autoantibody pro-
duction. [152-156] 
Signaling through TLR4 in 
the bleomycin model induces 
autoantibody production. 
[158] 
Treatment 
(drugs em-
phasizing the 
role played 
by APCs and 
their recep-
tors) 
HCQ and glucocorticoids [55,56] 
Anti-IFN antibodies [57] 
Abetimus sodium [58] 
HCQ and glucocorticoids [113-116] 
Abatacept [110-112] 
Chaperonin 10 [118] 
Syk inhibitor, R788 [121] 
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lap between the polymorphisms within this gene [161] and 
most are located within the epitope binding region, the 
MHC-II variant probably determines the antigen against 
which auto-antibodies are produced and thus which clinical 
phenotype occurs. FcRs and TLRs expressed by APCs are 
crucial receptors of the immune system forming a bridge 
between innate and adaptive immunity. In autoimmunity 
these receptors appear to direct immune responses towards 
self by enabling the uptake of immune complexes containing 
(nucleic) self-antigens. These ICs induce the release of pro-
inflammatory cytokines, such as type I IFNs, by APCs and 
forces them to mature. These mature APCs then induce the 
differentiation and proliferation of auto-reactive T cells, a 
crucial event in the pathogenesis of autoimmunity. Next to 
this the type I IFN system is unequivocally entangled in the 
pathogenesis of SLE and appears to have contributing roles 
to both RA and SSc. These findings underscore the potential 
of treatments aimed at APCs. Accordingly, in the past, pre-
sent and future the most promising targets in the enduring 
battle against autoimmunity appear to be these cells them-
selves, their receptors and their products.  
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